The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

About The Study: This cross-sectional study showed websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially informed and sometimes misinformed potential ...

Losing weight on a GLP-1 medication can have emotional and physical effects. Some changes are easier to handle than others, but users say the benefits are worth the effort.

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Attribution (BY): Credit must be given to the creator. Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long-acting peptide therapeutics for type 2 diabetes and ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.